Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 22, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 850,000 ordinary shares of 25 pence each.
- Purchase Price: 1,410.6260 pence per share.
- Treasury Holdings: 196,741,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,789,467,364 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the open market purchase of 850,000 shares. This transaction was executed in accordance with authority granted by shareholders at the Annual General Meeting on May 17, 2006. The purchased shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase by multiplying the 850,000 shares by the price of 1,410.6260 pence.
- Confirm the updated total share capital structure (5,789,467,364 shares in issue plus 196,741,678 Treasury shares).
- Review the May 17, 2006 Annual General Meeting minutes to understand the full scope of the share buyback authorization.